Trump signs executive order calling for split MMR, one vaccine per visit

President Donald Trump signed an executive order Monday that recommends childhood vaccines be administered one at a time at separate visits, calls for the combined measles, mumps and rubella (MMR) shot to be split into three single-disease injections, and presses states to rewrite school vaccination requirements around a narrower federal list. The order also directs the attorney general to pursue legal challenges against states over religious and medical vaccination exemptions.

For primary care practices, the operational weight sits in the second half of that list. No manufacturer sells standalone measles, mumps or rubella vaccines in the United States, so the MMR provision cannot be acted on today.

The push to states can move immediately, and it is built to move without waiting on the litigation that has held up the federal immunization schedule since March.

"For example, at one year, you should have five separate visits for vaccines rather than getting them all in the same day," Trump said.

The order sorts childhood immunizations into three categories. Eleven are recommended for all children: measles, mumps, rubella, diphtheria, tetanus, pertussis, polio, Haemophilus influenzae type B, pneumococcal disease, human papillomavirus and varicella. A second category covers high-risk groups, and a third moves the rest to shared clinical decision-making. Nothing is withdrawn from the market, and the order says access to vaccines currently available will be preserved.

Influenza and COVID-19 land in the shared decision-making category, as Trump said at the event. Hepatitis A and hepatitis B appear twice, listed under both high-risk groups and shared decision-making, a duplication the order does not explain. Trump added that hepatitis B should not be given until age 14 or 15. The federal schedule restored by the March ruling recommends a birth dose, though ACIP moved in December to make it optional for newborns of mothers who test negative, before the court intervened.

Trump also raised the possibility that the MMR components are dangerous when given in combination. "Together, there could be a possibility they're quite lethal, and separately, it looks like they are not at all lethal, but just very effective," he said.

Asked about the claim by a reporter during the question period that followed the signing, Trump backed away from it and attributed it to what some people say. Combination childhood vaccines are tested in clinical trials before licensure and tracked for years afterward. No such effect has been documented.

Stephen Miller, White House deputy chief of staff for policy, aimed the case for the order at clinicians as much as at manufacturers. He said parents are pressured weeks after childbirth to accept five, six or seven shots at once, and that the current schedule puts children on a path to 70 to 90 shots, which he called wantonly excessive.

"The pressure from the pharmaceutical industry and from aspects of the medical industry to pump your kids full of shots days after birth with no understanding the long-term consequences has been a medical travesty," Miller said. He said the order leaves the decision to the parent and the physician.

Four different counts of how many shots American children receive circulated on Monday. Trump said 72 jabs. Kennedy said it could be up to 94. Miller said 70 to 90. The White House fact sheet accompanying the order gives a fourth figure: at least 84 doses in at least 57 shots for 17 diseases in 2024, plus the RSV monoclonal antibody, against 23 doses in seven shots for seven diseases in 1980.

What the order does that the courts have not stopped

Federal recommendations were narrowed in January from 17 routinely recommended diseases to 11, moving respiratory syncytial virus, hepatitis A, hepatitis B and meningococcal vaccines into high-risk or shared clinical decision-making categories.

A federal judge in Boston stayed that change in March after finding it did not follow proper administrative procedure. The case is on appeal, and the pre-June 2025 schedule remains the operative federal one.

Heidi Overton, deputy assistant to the president for domestic policy, said the order is designed to bypass that timeline. She said the Dec. 5 presidential memorandum produced the HHS scientific assessment and the schedule overhaul, and that those actions have since been held up in court. The order, she said, puts the assessment in front of states directly. Its text says as much, citing litigation over ACIP's composition and the federal schedule as the reason for further action.

"We are going to be working directly with states so that we're not reliant on the court case to resolve," Overton said. "We are doing it right away so that parents get the benefit from state laws changing."

Overton said 28 states have declined to follow CDC recommendations since January and are working with outside organizations including the American Academy of Pediatrics (AAP).

She said the administration wants willing states to write the HHS assessment into state law, so that families enrolling children in school are not required to meet requirements for vaccines no longer recommended for all children. She said the measles vaccine is still recommended for all children.

The enforcement language sits in Section 4. It directs the attorney general to further legal actions challenging state laws that conflict with obligations on parental authority, religious freedom, disability accommodations and equal protection, including obligations to provide religious and medical exemptions from immunization requirements. A second provision reaches further: the Departments of Justice, Education and HHS are directed to ensure their contractors and grantees, including states and localities, comply with those same obligations, which ties federal money to the question.

The order's language toward states is otherwise advisory. It says states and territories are advised to review the recommendations and consider updating laws governing school enrollment requirements. States, not the federal government, set those requirements.

Jay Bhattacharya, M.D., Ph.D., director of the National Institutes of Health, drew a distinction at the event between recommending a vaccine and requiring one. He said the measles vaccine is important if the country wants to control the outbreak, and that children should not be kept out of school because their parents made different decisions than other parents.

Overton likewise said the measles vaccine remains recommended for all children.

The three-shot version does not exist

Merck stopped producing its standalone measles (Attenuvax), mumps (Mumpsvax) and rubella (Meruvax II) vaccines in 2008 and told the Advisory Committee on Immunization Practices on Oct. 21, 2009, that it would not resume production. The company said it had heard from organizations including AAP's Committee on Infectious Diseases, which held that separating the antigens would delay protection and add both injections and office visits per child.

Reviving the monovalent shots is not a matter of restarting a production line. Manufacturers would need new clinical trials, reconfigured facilities and three separate FDA approvals. The order itself conditions the MMR provision on such products becoming domestically available, and gives HHS 90 days to present plans for offering single vaccines, including by working with the private sector and other countries. The same section guarantees that combination vaccines will remain available.

Miller pointed to Japan as proof the approach can work. "Why is it that in Japan you can get a separate measles shot, a separate mump shot, a separate rubella shot, but in America it has to all be packaged together?" he said.

Japan is the closest thing to a real test of the idea, and the record there is more complicated than that. It withdrew MMR in 1993 after an unexpectedly high rate of aseptic meningitis tied to the mumps component and moved to single-antigen vaccines. Since 2006, its routine schedule has used two doses of a combined measles-rubella vaccine, with mumps offered separately as a voluntary shot. That is a bivalent vaccine plus one optional monovalent, not the three separate shots Miller described.

The results are the part worth reading before adopting the model. A 2004 analysis in Vaccine examining Japan's withdrawal of both MMR and combined DTP found the changes reduced immunization rates and increased disease rates, even though monovalent vaccines were available to replace them.

The spacing recommendation reaches further than MMR. Giving each vaccine its own appointment multiplies visits per child, and every added appointment is another opportunity for a no-show. Public health experts have argued the arithmetic works against coverage rather than for it, leaving children susceptible to vaccine-preventable disease in the gaps between visits.

What family physicians are being told

The framing physicians will meet across the exam table came from a mother who spoke at the event, one of the parents Trump introduced as the administration's "MAHA moms." "I'm not anti-vaccine at all. I'm pro-vaccine, but we want to be able to have the freedom to space it out and to choose which one works for our child," she said.

Sarah C. Nosal, M.D., FAAFP, president of the American Academy of Family Physicians (AAFP), was asked about staggered schedules in an interview with Medical Economics just days before the order.

"We really strongly recommend that patients receive the full appropriate vaccination dosing regimens at each scheduled appointment," Nosal said. "That doesn't mean I'm going to turn a patient away who declines that approach, but it is absolutely going to be my recommended and effective approach for vaccination."

Most parents who ask for a reduced or staggered schedule choose the standard one once they have talked through the evidence, Nosal said. She framed the trade-off in terms families feel directly: the standard schedule means fewer doctor's visits, and fewer missed school and work days.

AAP has continued to publish its own schedule. AAFP published its own 2026 child, adolescent and adult immunization schedules in March, developed with other medical organizations and the Vaccine Integrity Project, and its childhood schedule aligns with AAP's. A separate Executive Order 14407, signed May 29 directed CDC and ACIP to review the HHS assessment. Its practical effect was rhetorical. Monday's order is not.

The measles backdrop

The order lands as the country records its worst measles year in more than three decades. CDC counted 2,371 confirmed cases through July 30 across 34 outbreaks, already more than the total for all of 2025. Utah's outbreak, the largest active one, has passed 500 cases.

A national verification committee is reviewing U.S. measles elimination status this month, and the Pan American Health Organization is scheduled to rule in November on whether the country still qualifies as free of endemic transmission, a designation it has held since 2000. Canada lost its status in November 2025.

What HHS says comes next

Health Secretary Robert F. Kennedy Jr. said HHS has launched research comparing health outcomes in vaccinated and unvaccinated children and examining aluminum adjuvants and the timing of the hepatitis B vaccine, drawing on data sources including CDC's Vaccine Safety Datalink. He said the department will deliver the full response the order requires within 90 days.

Kennedy said the Task Force on Safer Childhood Vaccines, created by Congress in 1986 and dormant since 1998, has been reinstated and is examining the timing and sequencing of childhood vaccines, along with alternative adjuvants.

Kennedy cited a 1970 Wisconsin study he described as covering roughly 900,000 eight-year-olds and finding an autism rate below one in 10,000, against a current CDC figure of one in 31 children. He rejected the explanation that broader diagnosis accounts for the increase.

The paper appears to be Darold Treffert's "Epidemiology of Infantile Autism", published in Archives of General Psychiatry in 1970 and generally described as the first population-based autism prevalence study in the United States. It did not screen 900,000 children. Treffert counted children age 12 and under who came to attention or were under treatment in Wisconsin mental health clinics, hospitals and training schools between 1962 and 1967, a case-finding method that captures children already in the system. Later summaries of the paper put the prevalence it found between roughly 2.5 and 3.1 per 10,000.

Autism researchers have attributed much of the long-term rise to expanded diagnostic criteria, increased screening and greater awareness.

Decades of research involving millions of children has not found a link between childhood vaccines and autism. A retrospective cohort study of more than 2.5 million U.S. children, published July 28 in The Pediatric Infectious Disease Journal, found no association between the timing of a first MMR dose before age 2 and a later autism diagnosis.

Editor's note: This story has been updated with remarks from the White House event.